ClinicalTrials.gg

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Program

carfilzomib

Also written as “Carfilzomib”, “Cohort C1 & C2: KTX-1001 + Carfilzomib (KYPROLIS®)” and “Drug: Carfilzomib + Dexamethasone”.

Its studies are mostly in Multiple Myeloma · Amyloidosis · Small Cell Lung Carcinoma · Waldenstrom Macroglobulinemia · Hematologic Neoplasms, led by 5 companies.

Drug pageCarfilzomib: every studyMany companies study it; this page follows only the 33 they lead. All 157 studies, academic ones too, with its approvals and label.
Furthest: phase 4, since Apr 16, 201933 company-led studies, 4 open or runningNext primary completion: Apr 1, 2027 (phase 2)

Who develops it

Each company that leads studies of it, as its sponsor page counts them.

CompanyStudies it leadsFurthest phaseFirst studyNext primary completion
Amgenits history only230 open or runningphase 4since Apr 16, 2019Sep 6, 2005none ahead
AbbVieits history only32 open or runningphase 3since Nov 28, 2023Sep 27, 2013Jun 2027phase 2 · NCT02899052
Criteriumits history only30 open or runningphase 2since Oct 19, 2011Oct 19, 2011none ahead
Oncotherapeuticsits history only20 open or runningphase 2since Jan 3, 2013Jan 3, 2013none ahead
Sanofi22 open or runningphase 2since Jan 20, 2023Jan 20, 2023Apr 1, 2027phase 2 · NCT06356571

Also a collaborator on its studies: Bristol-Myers Squibb and Onyx Therapeutics.

How these companies relate is not in the registry. A license or acquisition is shown only with a dated source, such as a company release or filing.

History and studies of Sanofi only; the figures above count every company.

History and what’s ahead

From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.

  1. Jan 20, 2023First study: phase 2 study in Multiple MyelomaFirst studyNCT05704049 · 118 enrolled · Australia, Brazil, China and more
  2. Apr 5, 2024Phase 2 study in Plasma Cell Myeloma RefractoryNCT06356571 · 64 enrolled · United States
  3. Oct 26, 2026Primary completion moved from 2027-01-08 to 2027-04-01Date moved laterphase 2 · +3 months · NCT06356571

Ahead

  1. Apr 1, 2027Primary completion: phase 2 study in Plasma Cell Myeloma RefractoryNCT06356571

TargetBeta

“26S proteasome inhibitor”ChEMBL 37, by rule

Other programs on the same 38 targets

ProgramCompanyFurthest phaseStudies
BortezomibruleJohnson & Johnsonphase 485

Studies

All 2 Sanofi leads, newest first. Each opens its study page.

StudyPhaseStatusPrimary completionSize
NCT06356571Plasma Cell Myeloma Refractory · United States2Active, not recruitingApr 1, 202764
NCT05704049Multiple Myeloma · Australia, Brazil, China and more2Active, not recruitingDec 22, 2025118

How it is read

Names in the registry

  • “Carfilzomib”, 34 entries
  • “carfilzomib”, 3 entries
  • “Cohort C1 & C2: KTX-1001 + Carfilzomib (KYPROLIS®)”, 1 entry
  • “Drug: Carfilzomib + Dexamethasone”, 1 entry
  • “Drug: Carfilzomib + Lenalidomide + Dexamethasone”, 1 entry

Conditions, from the studies’ own filings

First seen by our ledger Nov 13, 2026.

What this can’t show

  • Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
  • Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
  • Primary completion dates are the sponsors’ estimates and often move.
  • A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.